Paul Nathan
Impact in
- Oncology top 0.1%
- Cutaneous Melanoma Detection and Management
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Ophthalmology top 0.2%
- Ocular Oncology and Treatments
Papers in
- Oncology 84
- Cutaneous Melanoma Detection and Management 36
- Cancer Immunotherapy and Biomarkers 29
- CAR-T cell therapy research 19
-
- Renal cell carcinoma treatment 47
- Co-authors
- Dirk Schadendorf (13 shared papers)Caroline Robert (13 shared papers)James Larkin (19 shared papers)Keith T. Flaherty (8 shared papers)Bruce G. MacMillan (13 shared papers)Reinhard Dummer (11 shared papers)Vicky Goh (6 shared papers)Claus Garbe (5 shared papers)
- Journals
- Annals of Oncology (34 papers)European Journal of Cancer (23 papers)The Lancet Oncology (13 papers)Journal for ImmunoTherapy of Cancer (9 papers)New England Journal of Medicine (7 papers)
- Partner nations
- United KingdomUnited StatesGermany
In The Last Decade
Paul Nathan
261 papers receiving 23.1k citations
Paul Nathan's Hit Papers
Peers
Comparison fields: 5 of 157
- Oncology 11.0k
- Ophthalmology 1.4k
- Molecular Biology 10.9k
- Cancer Research 2.1k
- Immunology 3.1k
Countries citing papers authored by Paul Nathan
This map shows the geographic impact of Paul Nathan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Nathan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Nathan more than expected).
Fields of papers citing papers by Paul Nathan
This network shows the impact of papers produced by Paul Nathan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Nathan. The network helps show where Paul Nathan may publish in the future.
Co-authors
The 25 scholars most cited alongside Paul Nathan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 272 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib Hit paper breakdown → | 2014 | 2163 |
| 2 | Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma Hit paper breakdown → | 2012 | 1820 |
| 3 | Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma Hit paper breakdown → | 2013 | 1579 |
| 4 | Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma Hit paper breakdown → | 2014 | 1551 |
| 5 | Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group Hit paper breakdown → | 2012 | 1225 |
| 6 | Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial Hit paper breakdown → | 2015 | 1129 |
| 7 | Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma Hit paper breakdown → | 2019 | 1048 |
| 8 | Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma Hit paper breakdown → | 2013 | 672 |
| 9 | Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma Hit paper breakdown → | 2021 | 670 |
| 10 | Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial Hit paper breakdown → | 2019 | 643 |
| 11 | Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study Hit paper breakdown → | 2017 | 536 |
| 12 | Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma Hit paper breakdown → | 2022 | 346 |
| 13 | 2011 | 324 | |
| 14 | Metastatic disease from uveal melanoma: treatment options and future prospects Hit paper breakdown → | 2016 | 315 |
| 15 | Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial Hit paper breakdown → | 2021 | 296 |
| 16 | 2010 | 283 | |
| 17 | 2016 | 266 | |
| 18 | 2018 | 222 | |
| 19 | 2015 | 220 | |
| 20 | 2018 | 219 |
About Paul Nathan
Paul Nathan is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Rehabilitation, Ophthalmology and Immunology, having authored 272 papers that have together received 23.8k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (47 papers), Melanoma and MAPK Pathways (47 papers), Cutaneous Melanoma Detection and Management (36 papers), Cancer Immunotherapy and Biomarkers (29 papers), Immunotherapy and Immune Responses (22 papers), Ocular Oncology and Treatments (21 papers), CAR-T cell therapy research (19 papers) and Wound Healing and Treatments (19 papers). The work is most often cited by research in Oncology (11.0k citations), Ophthalmology (1.4k citations), Molecular Biology (10.9k citations), Cancer Research (2.1k citations) and Immunology (3.1k citations). Paul Nathan has collaborated with scholars based in United Kingdom, United States and Germany. Frequent co-authors include Dirk Schadendorf, Caroline Robert, James Larkin, Keith T. Flaherty, Bruce G. MacMillan, Reinhard Dummer, Vicky Goh, Claus Garbe, Jaspal K. Juttla and Anup Vinayan. Their work appears in journals such as Annals of Oncology, European Journal of Cancer, The Lancet Oncology, Journal for ImmunoTherapy of Cancer and New England Journal of Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.